NEUN Stock Overview
Manufactures and sells nutritional supplements primarily in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Neurogenesis, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.0001 |
| 52 Week Low | US$0.0001 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -98.67% |
| 5 Year Change | -98.18% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| NEUN | US Personal Products | US Market | |
|---|---|---|---|
| 7D | 0% | 4.3% | 2.2% |
| 1Y | n/a | -12.0% | 31.6% |
Return vs Industry: Insufficient data to determine how NEUN performed against the US Personal Products industry.
Return vs Market: Insufficient data to determine how NEUN performed against the US Market.
Price Volatility
| NEUN volatility | |
|---|---|
| NEUN Average Weekly Movement | n/a |
| Personal Products Industry Average Movement | 8.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NEUN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine NEUN's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | n/a | Al Bieser | www.neurogenesis.com |
Neurogenesis, Inc. manufactures and sells nutritional supplements primarily in the United States. The company offers NeuBecalm’d, a nutritional supplement to reduce the effects of acute and chronic stress factors; NeuBecalm'd Chewables that reduces the effects of stress and enhance focus; and NeuRecover, a nutritional support for the natural replenishment of neurotransmitters depleted by the long-term use of alcohol. It also provides NeuReplenish, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the long-term use of chemical stimulants; NeuRelieve, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the long-term use of antianxiety drugs, and to be used in conjunction with professional support during the tapering process; and NeuSlim, which aids in the reduction of cravings (or urges) for simple carbohydrates, to reduce excessive appetite in general, and to assist in healthy moderation of nutritional needs.
Neurogenesis, Inc. Fundamentals Summary
| NEUN fundamental statistics | |
|---|---|
| Market cap | US$8.23k |
| Earnings (TTM) | -US$9.60k |
| Revenue (TTM) | US$1.07m |
0.0x
P/S Ratio0.0x
P/E RatioIs NEUN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NEUN income statement (TTM) | |
|---|---|
| Revenue | US$1.07m |
| Cost of Revenue | US$217.94k |
| Gross Profit | US$851.52k |
| Other Expenses | US$861.12k |
| Earnings | -US$9.60k |
Last Reported Earnings
Sep 30, 2007
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did NEUN perform over the long term?
See historical performance and comparison